Bendamustine Rituximab Br For First Line Chronic Lymphocytic Leukaemia

Found 3 free book(s)

Venetoclax and Obinutuzumab

nssg.oxford-haematology.org.uk

First line treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) or Small Lymphocytic Lymphoma (SLL): 1. In the presence of 17p deletion or TP53 mutation (NICE TA663- BLUETEQ required). OR 2. In the absence of 17p deletion or TP53 mutation in adult patients for whom Fludarabine, Cyclophosphamide and Rituximab ...

First, Line, Chronic, Rituximab, Leukaemias, Lymphocytic, First line, Chronic lymphocytic leukaemia

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

www.ema.europa.eu

IMBRUVICA as a single agent or in combination with rituximab or obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section5.1). IMBRUVICA as a single agent or in combination with bendamustine and rituximab (BR)is indicated

Chronic, Bendamustine, Rituximab, Leukaemias, Lymphocytic, Chronic lymphocytic leukaemia

Bendamustine +Rituximab (BR) for CLL